..., quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Hirudin Hirulog Argatroban Napsagatran Inogatran Efegatran DuP714...

...Y. Sasaki; S. Morii; T. Yamashita; J. Yamamoto The antithrombotic effect of the synthetic thrombin inhibitor (2R,4R)-4-methyl-1 -[N 2 -(3-methyl-1,2,3,4-tetrahydro-8-quin-olinesulfonyl)- L -arginyl]-2-piperidinecarboxylic acid mono-hydrate (argatroban) was investigated in cerebral vessels...

...Tsuyoshi Hara; Masahiro Iwamoto; Masanao Ishihara; Munehiro Tomikawa The preventive effect of argatroban, a synthetic thrombin inhibitor, on cerebral infarction was evaluated with ellagic acid (EA)-induced cerebral thromboembolism in rats. Platelet-rich thrombi containing fibrin and EA crystal were...

..., calphostin C, or BAPTA, further suggests that the process is dependent on phosphatidyl-inositol-3-kinase, protein kinase C, and calcium. However, the complete loss of thrombin-induced VEGF production upon treatment with argatroban, a derivative of arginine and a potent anticoagulant/antithrombin agent...

... anticoagulants interfere with the ECA. Hirudin Thrombin inhibitor Ecarin chromogenic assay Ecarin clotting time Argatroban © 2004 S. Karger AG, Basel 2004 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages...

...Jeanine M. Walenga Argatroban is a small molecule direct thrombin inhibitor. The main attributes of this synthetic drug are its rapid onset of anti-thrombin action, rapid reversibility of its anticoagulant effect, potent inhibition of clot-bound thrombin, absence of antibody formation and no need...

...Hidenobu Ikoma Argatroban is a synthetic direct thrombin inhibitor which has been used in Japan for three indications, namely, chronic arterial occlusion, acute cerebral thrombosis and hemodialysis in AT-deficient patients or in patients with decreased AT. In patients with chronic arterial...

... Argatroban Abstract Progress in molecular biology has stimulated interest in the structure and function of thrombin. It has improved our understanding of its central role in thrombogenesis and has clarified the molecular events of inhibitor binding. This development has resulted in the production...

... to determine the usefulness of argatroban, a direct thrombin inhibitor (DTI) that is not immunogenic and does not interact with heparin antibody, in answering this clinical need. Clinical outcomes (37-day period) for 568 argatroban-treated and 193 control patients demonstrated significantly reduced risks...

.... A large-scale study with bivalirudin in patients with acute MI (the HERO-2 trial) has not shown a reduction in mortality but a 30% reduction of reinfarction within 96 h. Hirudin and argatroban have been successfully used in patients with heparin-induced thrombocytopenia type II. Several orally active...

... of cerebral ischemia. A clinical study in Japan found that argatroban administered within 48 h of stroke symptom onset is safe and effective in reducing neurological impairment due to ischemic stroke. The implications of further clinical studies are discussed. Pathophysiology ofHaemostasis andThrombosis...